PepGen Inc. ( (PEPG) ) has released its Q2 earnings. Here is a breakdown of the information PepGen Inc. presented to its investors.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
PepGen Inc. is a clinical-stage biotechnology company focused on developing oligonucleotide therapeutics for severe neuromuscular and neurologic diseases, headquartered in Boston, Massachusetts. In its latest earnings report for the quarter ended June 30, 2025, PepGen Inc. reported a net loss of $23.1 million, reflecting a decrease from the previous year. The company’s operating expenses were primarily driven by research and development costs, which amounted to $18.4 million for the quarter. Despite the losses, PepGen maintains a cash position of $74.7 million, which is expected to fund operations into the second quarter of 2026. The company is actively seeking additional funding to continue its operations and advance its clinical programs. Looking forward, PepGen’s management remains focused on the development of its remaining clinical-stage product candidate, PGN-EDODM1, while navigating financial challenges and competitive pressures in the biotechnology sector.